Nautilus Biotechnology, Inc. (NAUT)

Market Cap	90.83M
Revenue (ttm)	n/a
Net Income (ttm)	-68.66M
Shares Out	126.15M
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	134,202
Open	0.7655
Previous Close	0.7877
Day's Range	0.7200 - 0.8100
52-Week Range	0.6600 - 3.0900
Beta	1.24
Analysts	Strong Sell
Price Target	1.75 (+143.06%)
Earnings Date	Jul 31, 2025

About NAUT

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 155
• Stock Exchange: NASDAQ
• Ticker Symbol: NAUT
• Website: https://www.nautilus.bio

Analyst Summary

According to one analyst, the rating for NAUT stock is "Strong Sell" and the 12-month stock price target is $1.75.

Price Target

$1.75

(143.06% upside)

Analyst Consensus: Strong Sell